It is not only good medical practice to ensure patients are fully involved in their treatment decisions, but it also improves subsequent compliance, and may even be cost effective. However, choosing treatments in MS is becoming increasingly complex, which means that ensuring patients understand all the issues is a challenge and time consuming. Preference sensitive care (which applies to current MS immunomodulatory treatments) is particularly vulnerable to the individual doctor's opinion and t...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Partnership and consent in MS treatment choice.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record